Q BioMed (OTCMKTS:QBIO) Downgraded by Zacks Investment Research

Q BioMed (OTCMKTS:QBIO) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports.

According to Zacks, “Q BioMed Inc. is a biomedical acceleration and development company. It focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. Q BioMed Inc. is based in New York. “

Separately, ValuEngine upgraded shares of Q BioMed from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st.

Shares of OTCMKTS:QBIO opened at $0.37 on Wednesday. The company has a market cap of $7.19 million, a PE ratio of -0.54 and a beta of 3.85. The company’s 50-day moving average price is $0.46 and its 200 day moving average price is $1.05. Q BioMed has a fifty-two week low of $0.34 and a fifty-two week high of $2.54.

Q BioMed (OTCMKTS:QBIO) last issued its quarterly earnings data on Tuesday, October 15th. The company reported ($0.17) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.05). As a group, sell-side analysts anticipate that Q BioMed will post -0.64 EPS for the current fiscal year.

About Q BioMed

Q BioMed Inc, a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89, a radiopharmaceutical therapeutic for the treatment of bone cancer pain therapies. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; BM-001 for the treatment of rare pediatric nonverbal autism spectrum disorder; and Uttroside-B for liver cancer.

Featured Article: How Buying a Call Option Works

Get a free copy of the Zacks research report on Q BioMed (QBIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Q BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Q BioMed and related companies with MarketBeat.com's FREE daily email newsletter.